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Abstract Regulation of nucleoside transporters is poorly under-
stood. We show that acute stimulation of protein kinase C (PKC)
causes a rapid increase in S-(4-nitrobenzyl)-6-thioinosine-sensi-
tive (human equilibrative nucleoside transporter 1, hENT1)
nucleoside uptake, in human cultured cells, which is not due to
increased metabolism and which can be blocked by PKC
inhibitors. Use of isoform-specific inhibitors indicates that PKC
N and/or O (but not K, L or Q) are responsible for the acute
effects. Down-regulation of PKC decreases hENT1-dependent
uridine uptake. These are the first data to show rapid PKC N/O-
dependent stimulation of hENT1 transport by a mechanism that
may involve activation of transporters at the membrane possibly
by post-translational modification of the protein. ß 2002 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Nucleoside transporters (NTs) are integral membrane pro-
teins that move a variety of nucleosides across cell membranes
[1^3] thereby regulating the intracellular and extracellular nu-
cleoside concentrations. NTs have been subdivided into two
major classes and a number of subclasses based on criteria
relating to substrate speci¢city, co-transport of cations and
inhibitor sensitivity [3]. Concentrative (CNTs) and equilibra-
tive (ENTs) NTs both transport nucleosides. However, in hu-
man cells and tissues, human equilibrative nucleoside trans-
porter 1 (hENT1) is the most widely distributed and is
expressed at high levels compared to the other transporters
[4]. In contrast, the CNTs and hENT2 are more tissue-speci¢c,
found mainly in the gastrointestinal and reno-hepato systems
(CNTs) and skeletal muscle (ENT2) [4^7]. The ENTs can be
further subdivided into two groups on the basis of their sensi-
tivity to a tight-binding inhibitor, S-(4-nitrobenzyl)-6-thioino-
sine (NBTI), which inhibits hENT1 (but not hENT2) at nano-
molar concentrations [1]. Since hENT1 is widely expressed it
is likely to be physiologically important for uptake of nucleo-
sides and nucleoside analogs in many cells and tissues.
While there are considerable data relating to the mecha-
nisms which underlie regulation of other transporters (e.g.
[8^12]), little is known about the regulation of NTs. Nucleo-
side uptake varies during the cell cycle [13], and as a con-
sequence of di¡erentiating and other growth-related stimuli
[14^20]. In general, cellular di¡erentiation appears to lead to
an increase in CNT-like transport and a decrease in ENT-
like transport, although there are clearly cell and tissue-spe-
ci¢c di¡erences. As a consequence, there is little consensus in
the literature as to the nature of the regulation of NTs in
di¡erent tissues. The recent cloning and sequence analysis of
several members of the NT family suggests that direct post-
translational modi¢cation by intracellular kinases is a possi-
ble mechanism of regulating activity of these proteins. Pro-
tein kinase C (PKC) has been implicated in long-term regu-
lation of NTs since there is a phorbol 12-myristate 13-acetate
(PMA)-dependent decrease in NBTI-sensitive nucleoside
transport in HL-60 cells induced to di¡erentiate [14,16]. In
cultured bovine chroma⁄n cells, long-term PMA treatment
decreases adenosine transport [21]. However, acute regulation
of NBTI-sensitive transport by PKC has not been shown
and the underlying mechanisms responsible for these e¡ects
have not been identi¢ed for any NT. In order to clarify the
role of PKC in regulation of hENT1 in human cells, we used
cell lines (MCF-7 and HeLa) which have well-characterized
NTs (possessing both hENT1 and hENT2 but no CNTs
[13,22]) plus treatment conditions that we have previously
shown to stimulate PKC activity acutely and lead to a con-
sistent down-regulation of PKC [23]. We show that PKC
regulates hENT1-dependent nucleoside uptake (rather than
metabolism) acutely and tonically, and that the PKC iso-
forms N and/or O appear to be involved. In addition, we
propose that the increased uptake via hENT1 is due to an
apparent ‘activation’ of transporters already present at the
membrane and also results in a change in a⁄nity for sub-
strate possibly by post-translational modi¢cation of the pro-
tein.
2. Materials and methods
2.1. Materials
Cell culture supplies were obtained from Gibco BRL (MD, USA),
[3H]uridine, [3H]formycin B and [3H]NBTI from Moravek (CA,
USA), PMA (K and L) and PKC inhibitors were from Calbiochem.
Non-tritiated formycin B was purchased from Alberta Nucleoside
Therapeutics (Edmonton, AB, Canada). The non-radioactive PKC
assay kit (SignaTECT) was from Promega (CA, USA). Complete
Protease Inhibitor pellets were from Boehringer Mannheim (Laval,
QC, Canada). All other reagents were from standard suppliers and
were of the highest grade available.
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2.2. Cell culture and transport assays
MCF-7 and HeLa cells were obtained from Dr. Linda Penn, Ontar-
io Cancer Institute, Toronto. All cell lines were con¢rmed to be my-
coplasma-free. Transport assays were conducted at room temperature
as previously described [23,24]. Transport bu¡er (20 mM Tris^HCl,
3 mM potassium diphosphate, 1 mM magnesium chloride, 2 mM
calcium chloride, 5 mM glucose, 130 mM N-methyl D-glucamine;
pH 7.4) contained permeant (10 WM) and radiolabeled nucleoside
([3H]uridine, [3H]formycin B, [3H]adenosine; speci¢c activities of
9.3, 14 and 22.8 Ci/mmol, respectively). At speci¢ed time points (with-
in the established linear phase of uptake), the permeant solution was
rapidly aspirated and the cells were washed at least twice in ice-cold
transport bu¡er. Cells were then solubilized in 1% Triton-X (Bioshop
Canada, ON, Canada) overnight at 4‡C, and aliquots taken to mea-
sure nucleoside uptake (by standard liquid scintillation counting).
Transport is expressed as pmol/106 cells. Kinetic parameters
(Vmax and Km) for uptake in the presence and absence of PMA
(500 nM, 10 min) were determined using various concentrations of
nucleoside (10^600 WM). For adenosine measurements, non-speci¢c
background was reduced by conducting experiments in the presence
of L-adenosine at 1/4 ¢nal concentration D-adenosine. Presence of
L-adenosine was determined to have no e¡ect on overall uptake
(data not shown). Results were calculated using non-linear regression
analysis (GraphPad, PRISM). To inhibit hENT1-dependent trans-
port, assays were conducted in the presence of NBTI (100 nM). For
short-term stimulation by PMA, cells were preincubated in PMA (or
vehicle, 0.03% dimethyl sulfoxide, DMSO) for 10 min prior to the
transport assay and the same concentration of PMA was included
in the permeant solution. For inhibition of total PKC activity, cells
were preincubated in the presence or absence (control) of cheleryth-
rine chloride (1 WM, IC50 = 660 nM, 30 min) prior to incubation in
the presence of PMA plus chelerythrine chloride (10 min). To in-
hibit the speci¢c PKC isoforms, cells were preincubated in the
presence or absence of Go« 6983 or Go« 6976 (500 nM, 15 min) prior
to the 10 min incubation in the presence of PMA plus inhibitor fol-
lowed by transport assay. Go« 6983 inhibits PKC isoforms K, L, Q, N
and O (IC506 60 nM) whereas Go« 6976 inhibits only K, L and Q
(IC506 60 nM) and does not a¡ect kinase activity of Ca2-indepen-
dent PKC isoforms (such as N and O) even at micromolar concentra-
tions. Stimulation of PKC activity was con¢rmed using a non-radio-
active PKC assay kit (SignaTECT) according to the manufacturer’s
instructions.
2.3. Isolation of plasma membrane
Plasma membrane fractions of MCF-7 cells were prepared by su-
crose gradient centrifugation according to published methods [25,26].
Brie£y, cells were trypsinized, resuspended in saline and centrifuged
(10 min, 1000Ug). Packed cells were resuspended in 1 mM ZnCl2 in
the ratio 1:10. A Polytron homogenizer was used for fragmentation of
cells. The nuclei and unbroken cells were removed by centrifugation
of the homogenate (3U1 min, 900Ug). Supernatants were centrifuged
(30 min, 11 000Ug) and the membrane pellets were resuspended in
9.25% sucrose. The membrane fractions were separated using a su-
crose gradient (15^60%) containing 0.5 mM ZnCl2 and 5 mM potas-
sium phosphate. The fractions at 20/30% sucrose layers were collected
and stored at 380‡C in 15% (v/v) DMSO. To con¢rm isolation of
plasma membrane fractions, standard sodium dodecyl sulfate^polyac-
rylamide gel electrophoresis (SDS^PAGE) protein analysis was con-
ducted on aliquots of plasma membrane and cytosolic fractions fol-
lowed by immunodetection of NaKATPase, a plasma membrane
protein, using standard techniques [27].
2.4. NBTI binding
Binding assays (1 ml ¢nal volume) were performed at room temper-
ature in 10 mM Tris (pH 7.1) with membrane preparations or in
10 mM Tris^HCl, 100 mM KCl, 0.1 mM MgCl2W6H2O, 0.1 mM
CaCl2W2H2O (pH 7.4) with whole cells. Samples (plasma membranes
or whole cells) were incubated with increasing concentrations of
[3H]NBTI (0.1^7.45 nM) in either the absence or presence of 10 WM
NBTI [28]. After incubation for 40 min (membranes) or 50 min
(whole cells), the reaction was stopped by dilution with 5 ml of ice-
cold binding bu¡er, rapidly ¢ltered through Whatman GF/B ¢lters,
followed by one wash with 5 ml of the same bu¡er. Filters were
analyzed for radioactive content by standard liquid scintillation
counting.
3. Results
Both MCF-7 and HeLa cells show equilibrative nucleoside
transport, which is approximately 80% NBTI-sensitive (Fig.
1A). To determine if PKC regulates hENT1-dependent nu-
cleoside transport, we measured uptake of 10 WM uridine in
MCF-7 and HeLa cells following both short-term stimulation
of PKC (10 min, 100 nM PMA) and down-regulation of PKC
(24 h, 100 nM PMA). Acute stimulation of PKC in both
MCF-7 and HeLa cells leads to a signi¢cant increase (control
versus PMA-treated, Student’s paired t-test, P6 0.05, MCF-7,
n = 3, HeLa, n = 6) in hENT1-dependent uridine uptake (Fig.
1A). We con¢rmed that hENT1-dependent uptake is stimu-
lated (rather than hENT2) since NBTI abolished the PMA-
dependent stimulation. We also con¢rmed the stimulation was
PKC-dependent since the presence of chelerythrine chloride,
which inhibits all PKC isoforms, abolished the PMA-depen-
dent stimulation. Uridine uptake in cells treated with vehicle
only, the non-active K analog of PMA and chelerythrine only
showed no di¡erence to control (data not shown). We con-
¢rmed that our treatment conditions did indeed lead to acti-
vation of PKC by measuring PKC activity in cell lysates of
treated and untreated MCF-7 cells. We found that total PKC
activity increased at least six-fold in treated cells (Fig. 1B).
Since human cell lines possess a number of PKC isoforms,
we focussed on MCF-7 cells for further analysis of the iso-
forms responsible for the observed e¡ects using the isoform-
speci¢c inhibitors, Go«6983 and Go«6976. The presence of
Go«6983 clearly abolished the PMA-dependent stimulation of
Fig. 1. Modulation of PKC activity regulates hENT1-dependent uri-
dine uptake in human cells. A: Uridine (10 WM) uptake in cells
treated acutely with 100 nM L-PMA or media only (Con) for
10 min. Cells treated with vehicle only (0.03% DMSO) or the non-
active PMA analog, K-PMA, showed no di¡erence in uptake com-
pared to control (untreated) cells (data not shown). The speci¢c
hENT1 inhibitor, NBTI (100 nM), blocked at least 80% of uridine
uptake (NB). There was no signi¢cant stimulation of remaining up-
take by PMA (NB/PMA). Cells treated for 15 min with the PKC
inhibitor, chelerythrine chloride (1 WM), prior to treatment with
PMA (plus inhibitor) showed no signi¢cant increase in uridine up-
take (Chel/PMA). Pooled data, mean þ S.E.M., nv 3, (except
NBTI+PMA and NBTI in MCF-7, mean þ S.D., n = 2), each experi-
ment conducted in triplicate. B: Six-fold stimulation of PKC activ-
ity by PMA determined as outlined in Section 2.
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uridine uptake in MCF-7 cells (Fig. 2) suggesting that either
PKC N and/or O were responsible for the observed e¡ects.
It has been shown in DDT-MF2 cells (a hamster muscle cell
line) that PKC can inhibit adenosine kinase leading to an
apparent increase in the e¥ux of nucleoside [29] suggesting
that PKC may act on metabolic pathways related to nucleo-
side uptake rather than transport itself. Therefore to test if
PKC was acting at the level of metabolism, we measured the
uptake of formycin B, a poorly metabolized nucleoside ana-
log, following stimulation of PKC (Fig. 3) and found that
transport increased to a similar extent to that observed for
uridine. If PKC is regulating hENT1-dependent uptake, then
down-regulation of PKC should lead to a loss of the acute
stimulated response. To test this, we subjected cells to long-
term or chronic treatment with PMA (which leads to the
down-regulation of PKC, [23]) and observed an overall de-
crease in hENT1-dependent uptake of uridine (Fig. 4). Uptake
was no longer acutely stimulated by PMA and overall levels
of uridine uptake were lower than control suggesting that
PKC is also involved in the tonic or long-term regulation of
hENT1.
The mechanism by which PKC might be regulating hENT1
is not clear although either phosphorylation (altering a⁄nity
for substrate) and/or modulation of tra⁄cking of transporters
to the plasma membrane are possible. Therefore we measured
changes in Km and Vmax for both uridine and adenosine up-
take in the presence and absence of PMA. We were unable to
conclusively determine if there were signi¢cant changes in af-
¢nity in the PMA-treated cells. However, overall uptake
clearly increased (adenosine, Vmax control 40.9 þ 4.2 pmol/
mg/s compared to Vmax PMA 124.1 þ 15.5 pmol/mg/s,
mean þ S.E.M., n = 4; uridine, Vmax control 58.4 þ 18 pmol/
mg/s compared to Vmax PMA 74 þ 16 pmol/mg/s, mean þ
S.E.M., n = 8). The overall increase in uptake could be the
consequence of an increase in the number of individual
hENT1 proteins at the membrane (as is seen in the rapid
activation of the glucose transporter in response to insulin
[27]). Since well-characterized antibodies against hENT1 are
not widely available, we measured changes in kinetic param-
eters of NBTI binding to whole cells in the presence and
absence of PMA. NBTI is a high a⁄nity inhibitor that binds
to hENT1 protein and can be used as a marker of hENT1
presence. Following acute stimulation with PMA, there was
no change in NBTI binding or a⁄nity (Bmax control
1.01 þ 0.04 pmol/mg protein compared to Bmax PMA
1.01 þ 0.06 pmol/mg protein; Kd control 0.25 þ 0.02 nM com-
pared to Kd PMA 0.21 þ 0.03 nM, mean þ S.D., n = 2). These
data suggest that the overall number of hENT1 binding sites
have not changed and that tra⁄cking of additional hENT1 to
the membrane does not occur. However, since both plasma
membrane and internal NBTI binding sites have been de-
scribed [25,30], we measured NBTI binding to puri¢ed plasma
membranes to determine the presence of hENT1 available to
transport at the membrane. Plasma membranes were puri¢ed
(as con¢rmed by protein analysis, Fig. 5). NBTI binding to
puri¢ed plasma membranes of MCF-7 cells in the presence of
PMA (100 nM, 10 min) showed no signi¢cant di¡erence in
overall binding (Bmax control 2.83 þ 0.22 pmol/mg protein
compared to PMA-treated 2.42 þ 0.35 pmol/mg protein,
mean þ S.E.M., n = 3). However, there was a signi¢cant in-
crease in a⁄nity (Kd control 0.17 þ 0.05 nM compared to Kd
PMA-treated 0.07 þ 0.02 nM, mean þ S.E.M., n = 3, P6 0.05,
unpaired t-test). These data suggest that activation of PKC by
PMA leads to e¡ects on hENT1 at the plasma membrane
Fig. 2. PKC N and/or O are involved in hENT1 regulation. The
PMA-induced increase in uridine (10 WM) uptake is inhibited by Go«
6983 (Calbiochem, inhibits K, L, Q, N and O) but not Go« 6976 (inhib-
its only K, L and Q). MCF-7 cells were treated in the presence and
absence of inhibitors (500 nM, 15 min) prior to measurement of up-
take. Pooled data, mean þ S.D., nv 2, each experiment conducted in
triplicate.
Fig. 3. PKC activation increase uptake and not metabolism. PMA-
stimulation leads to a comparable increase in uptake of the non-me-
tabolized nucleoside analog, formycin B (10 WM), compared to uri-
dine (10 WM) in MCF-7 and HeLa cells. Pooled data, mean þ
S.E.M., nv 3, each experiment conducted in triplicate, n.d. = not de-
termined.
Fig. 4. Down-regulation of PKC leads to a loss of PMA stimulated
increases in uptake and an overall decrease in uridine uptake.
Chronic treatment with PMA (100 nM, 24 h) leads to a decrease
(approximately 50%) in uridine (10 WM) uptake suggesting that
PKC is involved in tonic regulation of hENT1 activity. Pooled
data, mean þ S.E.M., nv 3, each experiment conducted in triplicate.
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which result in functional changes and increased substrate
uptake.
4. Discussion
We show that PKC acts in a short-term manner to rapidly
a¡ect hENT1-dependent nucleoside uptake in human cells
and that the isoforms N and/or O are responsible. These are
the ¢rst data to show that hENT1 is subject to rapid regula-
tion by an intracellular signaling pathway and that this regu-
lation appears to occur at the location of the membrane pos-
sibly by converting ‘inactive’ or ‘unavailable’ transporters to
‘active’ or ‘available’ transporters. We found that both HeLa
and MCF-7 cells possess predominantly hENT1-type trans-
port, as previously described [13,22]. Levels of NBTI-insensi-
tive transport in HeLa were lower than have been reported by
others [31] although the relative proportions of NBTI-sensi-
tive and -insensitive transport have been shown to vary con-
siderably during the cell cycle [13] with overall similar levels to
ours. In addition, in contrast to previous studies, our assays
were conducted in serum-free conditions that lead to varia-
tions in transporter pro¢le in these cells. For both HeLa and
MCF-7 we show that long-term treatment with PMA and
down-regulation of PKC is associated with a decrease in
NBTI-sensitive nucleoside transport con¢rming previous ¢nd-
ings in a number of systems [18,20,24] and suggesting the
possibility of transcriptional regulation. Acute stimulation of
PKC leads to an increase in hENT1-dependent nucleoside
uptake which appears to correlate with an overall increase
in active transporters at the plasma membrane but does not
appear to correlate with tra⁄cking of proteins from intracel-
lular sites. The underlying mechanisms responsible for these
e¡ects are not clear but studies of other transporters suggest
several possible pathways such as direct phosphorylation [11]
and indeed, the hENT1 protein has a number of consensus
kinase sites, including PKC and casein kinase [5]. In the
mouse, a splice variant of ENT1 exists which lacks a casein
kinase II (CKII) consensus site [32] and it is possible that
hENT1 is regulated by PKC via other kinases, such as
CKII, or phosphatases, as has been previously suggested
[23]. Other mechanisms of transporter regulation that have
been described include redistribution to the plasma membrane
to modulate transport activity [8,9,10]. Although subcellular
locations [25] and intracellular pools of NBTI-sensitive NTs
have been described [30], it would appear that acute stimu-
lation of PKC does not regulate hENT1-tra⁄cking in MCF-7
and HeLa cells. However, since apparent plasma surface NTs
can be transiently increased in certain cells [33], regulated
tra⁄cking to the cell membrane may occur in a cell or tis-
sue-speci¢c manner, possibly under the regulation of other
pathways [34]. Up-regulation of NBTI-binding sites has
been described in proliferating cells and certain tumors [35]
but cellular di¡erentiation has also been shown to have no
e¡ect on number NBTI-binding sites [17]. The presence of two
populations of NBTI-binding sites with di¡ering a⁄nities has
also been previously reported [36] although the functional
signi¢cance of these observations was not clear. Interpretation
of these data has been problematic and physiological rele-
vance and underlying mechanisms unclear. In contrast, our
studies suggest that there is a correlation between changes
in hENT1 activity and NBTI a⁄nity at the plasma membrane
which we propose is due to an ‘activation’ of a population of
hENT1 proteins already present in the membrane resulting in
increased nucleoside uptake, and, coincidentally, a subtle
change in the binding a⁄nity for NBTI. This would not be
unexpected given the overlapping sites of NBTI binding and
substrate translocation that have been proposed for hENT1
[1]. However, since hENT1 activity is likely subject to com-
plex regulation that is tissue and species-speci¢c [37,38], cau-
tion should be still used when inferring functional status of
hENT1 based on changes in a⁄nity or number of binding
sites for NBTI. Regulation of transporters by ‘activation’ of
a population of proteins already present at the membrane has
previously been described most notably for the GLUTs (equi-
librative glucose transporters) [27] and the glycine transporter,
GLYT1b [39], suggesting that cells use similar regulatory
mechanisms for di¡erent transport proteins.
The PKC isoforms involved in regulating hENT1 have not
previously been identi¢ed. We show in this paper that
hENT1-dependent nucleoside transport is regulated by the
novel PKC isoforms, N and/or O. PKC O is involved in cellular
proliferation [40], which may require increased nucleoside up-
take to meet metabolic demands. In addition, tamoxifen,
which causes a selective induction (and down-regulation) of
PKC O in MCF-7 cells [41], inhibits NBTI-sensitive uridine
transport by an estrogen-receptor (ER) independent mecha-
nism and leads to decrease in a⁄nity for NBTI without a
change in overall binding sites [22], (i.e. down-regulation of
PKC O leads to the opposite of the acute e¡ect we see with
stimulation of PKC N/O). We have previously shown that ta-
moxifen inhibits both ER stimulated and unstimulated
hENT1-dependent uridine uptake [42] suggesting that PKC
O may be a key component of NT regulation, particularly in
MCF-7 cells.
Rapid regulation of hENT1 is most likely due to e¡ects at
the protein level. However, the decrease in hENT1-dependent
uptake following down-regulation of PKC is more likely to be
a consequence of transcriptional regulation as has been de-
scribed for NTs in other systems [37,38] and indeed, the pro-
moter region of hENT1 contains regulatory consensus sites
that suggest mechanisms which could be linked to PKC sig-
naling pathways [43].
While we have identi¢ed parts of the intracellular signaling
pathway that regulates hENT1, the initiating extracellular sig-
nals remain elusive. Factors (e.g. cytokines and hormones)
that stimulate cell proliferation and metabolism may also ac-
tivate pathways regulating uptake of nucleosides to accommo-
date increased use of nucleosides in nucleic acid synthesis and
metabolic pathways. Indeed, nerve growth factor stimulation
Fig. 5. SDS^PAGE analysis of MCF-7 plasma membrane and cyto-
solic fractions (15 Wg protein) probed with antibody against K1 sub-
unit of NaKATPase as outlined in Section 2.
FEBS 26012 12-4-02
I. Coe et al./FEBS Letters 517 (2002) 201^205204
of chroma⁄n cells leads to increased uptake with decreased
a⁄nity for adenosine, similar to our ¢ndings, suggesting that
there may be some common underlying mechanisms in di¡er-
ent tissues [17]. However, further work is required to elucidate
the other components of the signaling pathways that regulate
these integral membrane proteins.
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